New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 24, 2019 - The FDA approved Amgen’s Mvasi (bevacizumab-awwb), for recurrent glioblastoma in adults.
Download PDF
Return to publications
